LXRX Q4 2024 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+3682.6% YoY

Gross Profit

$621,0002.3% margin

Operating Income

-$33M-123.3% margin

Net Income

-$34M-127.2% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+1417.4%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$298M

Total Liabilities

$152M

Stockholders' Equity

$146M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$702,000	+3682.6%
Gross Profit	$621,000	-$14M	+104.4%
Operating Income	-$33M	-$47M	+30.0%
Net Income	-$34M	-$50M	+32.1%